

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
19 June 2003 (19.06.2003)

PCT

(10) International Publication Number
WO 03/049741 A1

(51) International Patent Classification⁷: **A61K 31/5377**,
31/428, A61P 25/00

(21) International Application Number: PCT/EP02/13761

(22) International Filing Date: 5 December 2002 (05.12.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
01129228.1 10 December 2001 (10.12.2001) EP

(71) Applicant: **F. HOFFMANN-LA ROCHE AG** [CH/CH];
Grenzacherstrasse 124, CH-4070 Basel (CH).

(72) Inventors: **FLOHR, Alexander**; St. Galler-Ring 142,
CH-4054 Basel (CH). **JAKOB-ROETNE, Roland**;
Oberer Baselblick 37, 79595 Inzlingen (DE). **NOR-**
CROSS, Roger, David; Alte Saline, 20, CH-4310
Rheinfelden (CH). **RIEMER, Claus**; Optizstrasse 5,
79110 Freiburg (DE).

(74) Agent: **POPPE, Regina**; 124 Grenzacherstrasse,
CH-4070 Basel (CH).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU,
ZA, ZM, ZW.


(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: UREAS OF 2-AMINOBENZOTHAZOLES AS ADENOSINE MODULATORS




(57) Abstract: The present invention relates to the use of compounds of the general formula (I) and to pharmaceutically acceptable acid addition salts thereof for the manufacture of medicaments for the treatment of diseases, related to the adenosine A₂receptor system like Alzheimer's disease, Parkinson disease, anxiety pain and other neurological disorders.

WO 03/049741 A1

- 1 -

UREAS OF 2-AMINOBENZOTHAZOLES AS ADENOSINE MODULATORS

The present invention relates to the use of compounds of the general formula



wherein

R is lower alkoxy or halogen;

- 5 R¹/R² are independently from each other hydrogen, lower alkyl, tetrahydropyran-4-yl or cycloalkyl, which is unsubstituted or substituted by one or two substituents, selected from the group consisting of halogen, lower alkoxy or hydroxy, or R¹ and R² form together with the N atom to which they are attached heterocyclic rings, selected from the group consisting of
- 10 2-oxa-5-aza-bicyclo[2.2.1]heptane,
3-endo-hydroxy-8-aza-bicyclo[3.2.1]octane,
2-aza-bicyclo[2.2.2]octane,
1-oxo-2,8-diaza-spiro[4.5]decane,
3-aza-spiro[5.5]undecane,
15 8-aza-spiro[4.5]decane,
1-oxa-8-aza-spiro[4.5]decane,
1,8,8-trimethyl-3-aza-bicyclo[3.2.1]octane,
[1,4]oxazepane,
2-oxa-5-aza-bicyclo[2.2.2]octane,
20 8-oxa-3-aza-bicyclo[3.2.1]octane,
1,4-diaza-bicyclo[3.2.1]octane,
2-aza-bicyclo[2.2.1]heptane,
3-aza-bicyclo[3.2.1]octane,

which rings may be unsubstituted or substituted by lower alkyl, or is selected from piperazinyl, unsubstituted or mono or di-substituted by lower alkyl, phenyl or oxo, or is selected from

5 piperidin-1-yl, substituted by $-(CH_2)_n-NR'S(O)_2$ -lower alkyl, $-C(O)NR'_2$ or $-(CH_2)_n$ -phenyl, wherein the phenyl ring is unsubstituted or substituted by lower alkyl;
R' is hydrogen or lower alkyl, independently from each other in case R'₂;

X is -O- or -CH₂- and

n is 0, 1, 2, 3 or 4

10 and to pharmaceutically acceptable acid addition salts thereof for the manufacture of medicaments for the treatment of diseases, related to the adenosine A₂ receptor system. Such diseases include Alzheimer's disease, Parkinson's disease, Huntington's disease, neuroprotection, schizophrenia, anxiety, pain, respiration deficits, depression, drug addiction, such as amphetamine, cocaine, opioids, ethanol, nicotine, cannabinoids, or
15 against asthma, allergic responses, hypoxia, ischaemia, seizure and substance abuse. Furthermore, compounds of the present invention may be useful as sedatives, muscle relaxants, antipsychotics, antiepileptics, anticonvulsants and cardioprotective agents for disorders such as coronary artery disease and heart failure. The most preferred indications in accordance with the present invention are those, which base on the A_{2A} receptor
20 antagonistic activity and which include disorders of the central nervous system, for example the treatment or prevention of Alzheimer's disease, certain depressive disorders, drug addiction, neuroprotection and Parkinson's disease as well as ADHD.

It has surprisingly been found that the compounds of general formula I are adenosine receptor ligands. Specifically, the compounds of the present invention have a
25 good affinity to the A_{2A}-receptor and a high selectivity to the A₁- and A₃ receptors.

Adenosine modulates a wide range of physiological functions by interacting with specific cell surface receptors. The potential of adenosine receptors as drug targets was first reviewed in 1982. Adenosine is related both structurally and metabolically to the bioactive nucleotides adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenosine
30 monophosphate (AMP) and cyclic adenosine monophosphate (cAMP); to the biochemical methylating agent S-adenosyl-L-methione (SAM); and structurally to the coenzymes NAD, FAD and coenzym A; and to RNA. Together adenosine and these related compounds are important in the regulation of many aspects of cellular metabolism and in the modulation of different central nervous system activities.

The receptors for adenosine have been classified as A₁, A_{2A}, A_{2B} and A₃ receptors, belonging to the family of G protein-coupled receptors. Activation of adenosine receptors by adenosine initiates signal transduction mechanism. These mechanisms are dependent on the receptor associated G protein. Each of the adenosine receptor subtypes has been classically characterised by the adenylate cyclase effector system, which utilises cAMP as a second messenger. The A₁ and A₃ receptors, coupled with G_i proteins inhibit adenylate cyclase, leading to a decrease in cellular cAMP levels, while A_{2A} and A_{2B} receptors couple to G_s proteins and activate adenylate cyclase, leading to an increase in cellular cAMP levels. It is known that the A₁ receptor system include the activation of phospholipase C and modulation of both potassium and calcium ion channels. The A₃ subtype, in addition to its association with adenylate cyclase, also stimulates phospholipase C and so activates calcium ion channels.

The A₁ receptor (326-328 amino acids) was cloned from various species (canine, human, rat, dog, chick, bovine, guinea-pig) with 90–95 % sequence identity among the mammalian species. The A_{2A} receptor (409-412 amino acids) was cloned from canine, rat, human, guinea pig and mouse. The A_{2B} receptor (332 amino acids) was cloned from human and mouse with 45 % homology of human A_{2B} with human A₁ and A_{2A} receptors. The A₃ receptor (317-320 amino acids) was cloned from human, rat, dog, rabbit and sheep.

The A₁ and A_{2A} receptor subtypes are proposed to play complementary roles in adenosine's regulation of the energy supply. Adenosine, which is a metabolic product of ATP, diffuses from the cell and acts locally to activate adenosine receptors to decrease the oxygen demand (A₁) or increase the oxygen supply (A_{2A}) and so reinstate the balance of energy supply: demand within the tissue. The actions of both subtypes is to increase the amount of available oxygen to tissue and to protect cells against damage caused by a short term imbalance of oxygen. One of the important functions of endogenous adenosine is preventing damage during traumas such as hypoxia, ischaemia, hypotension and seizure activity.

Furthermore, it is known that the binding of the adenosine receptor agonist to mast cells expressing the rat A₃ receptor resulted in increased inositol triphosphate and intracellular calcium concentrations, which potentiated antigen induced secretion of inflammatory mediators. Therefore, the A₃ receptor plays a role in mediating asthmatic attacks and other allergic responses.

Adenosine is a neuromodulator, able to modulate many aspects of physiological brain function. Endogenous adenosine, a central link between energy metabolism and neuronal activity, varies according to behavioural state and (patho)physiological conditions. Under conditions of increased demand and decreased availability of energy

(such as hypoxia, hypoglycemia, and/or excessive neuronal activity), adenosine provides a powerful protective feedback mechanism. Interacting with adenosine receptors represents a promising target for therapeutic intervention in a number of neurological and psychiatric diseases such as epilepsy, sleep, movement disorders (Parkinson or Huntington's disease), Alzheimer's disease, depression, schizophrenia, or addiction. An increase in neurotransmitter release follows traumas such as hypoxia, ischaemia and seizures. These neurotransmitters are ultimately responsible for neural degeneration and neural death, which causes brain damage or death of the individual. The adenosine A₁ agonists which mimic the central inhibitory effects of adenosine may therefore be useful as neuroprotective agents. Adenosine has been proposed as an endogenous anticonvulsant agent, inhibiting glutamate release from excitatory neurons and inhibiting neuronal firing. Adenosine agonists therefore may be used as antiepileptic agents. Adenosine antagonists stimulate the activity of the CNS and have proven to be effective as cognition enhancers. Selective A_{2a} antagonists have therapeutic potential in the treatment of various forms of dementia, for example in Alzheimer's disease, and of neurodegenerative disorders, e.g. stroke. Adenosine A_{2a} receptor antagonists modulate the activity of striatal GABAergic neurons and regulate smooth and well-coordinated movements, thus offering a potential therapy for Parkinsonian symptoms. Adenosine is also implicated in a number of physiological processes involved in sedation, hypnosis, schizophrenia, anxiety, pain, respiration, depression, and drug addiction (amphetamine, cocaine, opioids, ethanol, nicotine, cannabinoids). Drugs acting at adenosine receptors therefore have therapeutic potential as sedatives, muscle relaxants, antipsychotics, anxiolytics, analgesics, respiratory stimulants, antidepressants, and to treat drug abuse. They may also be used in the treatment of ADHD (attention deficit hyper-activity disorder).

An important role for adenosine in the cardiovascular system is as a cardioprotective agent. Levels of endogenous adenosine increase in response to ischaemia and hypoxia, and protect cardiac tissue during and after trauma (preconditioning). By acting at the A₁ receptor, adenosine A₁ agonists may protect against the injury caused by myocardial ischemia and reperfusion. The modulating influence of A_{2a} receptors on adrenergic function may have implications for a variety of disorders such as coronary artery disease and heart failure. A_{2a} antagonists may be of therapeutic benefit in situations in which an enhanced antiadrenergic response is desirable, such as during acute myocardial ischemia. Selective antagonists at A_{2a} receptors may also enhance the effectiveness of adenosine in terminating supraventricular arrhythmias.

Adenosine modulates many aspects of renal function, including renin release, glomerular filtration rate and renal blood flow. Compounds which antagonise the renal effects of adenosine have potential as renal protective agents. Furthermore, adenosine A₃


and/or A_{2B} antagonists may be useful in the treatment of asthma and other allergic responses or and in the treatment of diabetes mellitus and obesity.

Numerous documents describe the current knowledge on adenosine receptors, for example the following publications:

- 5 Bioorganic & Medicinal Chemistry, 6, (1998), 619-641,
 Bioorganic & Medicinal Chemistry, 6, (1998), 707-719,
 J. Med. Chem., (1998), 41, 2835-2845,
 J. Med. Chem., (1998), 41, 3186-3201,
 J. Med. Chem., (1998), 41, 2126-2133,
 10 J. Med. Chem., (1999), 42, 706-721,
 J. Med. Chem., (1996), 39, 1164-1171,
 Arch. Pharm. Med. Chem., 332, 39-41, (1999),
 Am. J. Physiol., 276, H1113-1116, (1999) or
 Naunyn Schmied, Arch. Pharmacol. 362, 375-381, (2000).

- 15 Furthermore, WO 01/57008 describes benzothiazolyl urea derivatives and their use as protein kinase inhibitors. These compounds are useful as inhibitors of tyrosine kinases that are important in hyper-proliferative diseases, especially in cancer and in the process of angiogenesis. The following compounds of formulae IA and IB are not encompassed by WO 01/57008.

- 20 Therefore, the present invention relates also to novel compounds of formula IA



wherein

R is lower alkoxy or halogen;

- 25 R¹¹ and R²¹ form together with the N atom to which they are attached heterocyclic rings, selected from the group consisting of
 2-oxa-5-aza-bicyclo[2.2.1]heptane,
 3-endo-hydroxy-8-aza-bicyclo[3.2.1]octane,

- 6 -


2-aza-bicyclo[2.2.2]octane,
 1-oxo-2,8-diaza-spiro[4.5]decane,
 3-aza-spiro[5.5]undecane,
 8-aza-spiro[4.5]decane,
 5 1-oxa-8-aza-spiro[4.5]decane,
 1,8,8-trimethyl-3-aza-bicyclo[3.2.1]octane,
 [1,4]oxazepane,
 2-oxa-5-aza-bicyclo[2.2.2]octane,
 8-oxa-3-aza-bicyclo[3.2.1]octane,
 10 1,4-diaza-bicyclo[3.2.1]octane,
 2-aza-bicyclo[2.2.1]heptane,
 3-aza-bicyclo[3.2.1]octane,
 which rings may be unsubstituted or substituted by lower alkyl,
 or is selected from
 15 piperidin-1-yl, substituted by $-(CH_2)_n-NR'S(O)_2$ -lower alkyl, $-C(O)NR'_2$ or
 $-(CH_2)_n$ -phenyl, wherein the phenyl ring is unsubstituted or substituted by lower
 alkyl;
 R' is hydrogen or lower alkyl, independently from each other in case R'_2 ;

X is $-O-$ or CH_2- ; and

20 n is 0, 1, 2, 3 or 4

and to pharmaceutically acceptable acid addition salts thereof.

The present invention relates also to novel compounds of formula IB



wherein

25 R is lower alkoxy or halogen;

R^{12} is lower alkyl and

R²² is cycloalkyl, substituted by one or two substituents, wherein the substituents are selected from the group, consisting of halogen, lower alkoxy or hydroxy;

X is -O- or CH₂-;

Novel compounds of formula IA, wherein X is -O-, are, for example, the following:

- 5 (1S,4S)-2-oxa-5-aza-bicyclo[2.2.1]heptane-5-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
- 3-*endo*-hydroxy-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
- 2-methyl-1-oxo-2,8-diaza-spiro[4.5]decane-8-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
- 10 1-oxo-2,8-diaza-spiro[4.5]decane-8-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
- 4-benzyl-4-hydroxymethyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
- 15 3-aza-spiro[5.5]undecane-3-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
- 8-aza-spiro[4.5]decane-8-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
- 2-aza-bicyclo[2.2.2]octane-2-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
- 20 1-oxa-8-aza-spiro[4.5]decane-8-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
- (R)-4-(1-hydroxy-ethyl)-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
- 25 (S)-4-(1-hydroxy-ethyl)-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
- 4-(methanesulfonylamino-methyl)-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
- piperidine-1,4-dicarboxylic acid 4-amide 1-[(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide],
- 30 (1R)-1,8,8-trimethyl-3-aza-bicyclo[3.2.1]octane-3-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
- 2-oxa-5-aza-bicyclo[2.2.2]octane-5-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
- 35 1,4-diaza-bicyclo[3.2.1]octane-4-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide or

(1S,4R)-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide.

Novel compounds of formula IA are also those, wherein X is $-\text{CH}_2$, for example, the following:

- 5 1-oxa-8-aza-spiro[4.5]decane-8-carboxylic acid (4-methoxy-7-piperidin-1-yl-benzothiazol-2-yl)-amide,
4-hydroxy-4-(4-methyl-benzyl)-piperidine-1-carboxylic acid (4-chloro-7-piperidin-1-yl-benzothiazol-2-yl)-amide or
4-benzyl-piperidine-1-carboxylic acid (4-chloro-7-piperidin-1-yl-benzothiazol-2-yl)-
10 amide.

- Novel compounds of formula IB, wherein X is $-\text{O}-$, are, for example, the following:
1-(4*cis*-fluoro-cyclohexyl)-3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-1-methyl-
urea,
1-(4,4-difluoro-cyclohexyl)-3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-1-
15 methyl-urea,
(*cis*)-1-(4-methoxy-cyclohexyl)-3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-1-
methyl-urea,
(*trans*)-1-(4-hydroxy-cyclohexyl)-3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-1-
methyl-urea,
20 (*cis*)-1-(4-hydroxy-cyclohexyl)-3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-1-
methyl-urea or
(*trans*)-1-(4-methoxy-cyclohexyl)-3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-1-
methyl-urea.

- Objects of the present invention are the compounds of formula IA or IB per se, the
25 use of compounds of formula I and their pharmaceutically acceptable salts for the
manufacture of medicaments for the treatment of diseases, related to the adenosine A_2
receptor, their manufacture, medicaments based on a compound in accordance with the
invention and their production as well as the use of compounds of formula I in the control
or prevention of illnesses based on the modulation of the adenosine system, such as
30 Alzheimer's disease, Parkinson's disease, Huntington's disease, neuroprotection,
schizophrenia, anxiety, pain, respiration deficits, depression, drug addiction, such as
amphetamine, cocaine, opioids, ethanol, nicotine, cannabinoids, or against asthma, allergic
responses, hypoxia, ischaemia, seizure and substance abuse. Furthermore, compounds of
the present invention may be useful as sedatives, muscle relaxants, antipsychotics,
35 antiepileptics, anticonvulsants and cardioprotective agents for disorders such as coronary
artery disease and heart failure. The most preferred indications in accordance with the

present invention are those, which base on the A_{2A} receptor antagonistic activity and which include disorders of the central nervous system, for example the treatment or prevention of Alzheimer's disease, certain depressive disorders, drug addiction, neuroprotection and Parkinson's disease as well as ADHD.

5 As used herein, the term "lower alkyl" denotes a saturated straight- or branched-chain alkyl group containing from 1 to 6 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, n-butyl, i-butyl, 2-butyl, t-butyl and the like. Preferred lower alkyl groups are groups with 1 - 4 carbon atoms.

The term "halogen" denotes chlorine, iodine, fluorine and bromine.

10 The term "lower alkoxy" denotes a group wherein the alkyl residues is as defined above, and which is attached via an oxygen atom.

The term "pharmaceutically acceptable acid addition salts" embraces salts with inorganic and organic acids, such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic
15 acid, tartaric acid, methane-sulfonic acid, p-toluenesulfonic acid and the like.

Preferred compounds of the present application for use against diseases, related to the A_{2a} receptor are compounds of formula I, wherein X is -O-, for example the following compounds:

(1S,4S)-2-oxa-5-aza-bicyclo[2.2.1]heptane-5-carboxylic acid (4-methoxy-7-morpholin-4-
20 yl-benzothiazol-2-yl)-amide,
3-*endo*-hydroxy-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
2-methyl-1-oxo-2,8-diaza-spiro[4.5]decane-8-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
25 1-oxo-2,8-diaza-spiro[4.5]decane-8-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
4-benzyl-4-hydroxymethyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
3-aza-spiro[5.5]undecane-3-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-
30 2-yl)-amide,
8-aza-spiro[4.5]decane-8-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
2-aza-bicyclo[2.2.2]octane-2-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,


- 1-oxa-8-aza-spiro[4.5]decane-8-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
 (R)-4-(1-hydroxy-ethyl)-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
 5 (S)-4-(1-hydroxy-ethyl)-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
 4-(methanesulfonylamino-methyl)-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
 piperidine-1,4-dicarboxylic acid 4-amide 1-[(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide],
 10 1-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-3-(tetrahydro-pyran-4-yl)-urea,
 4-isopropyl-piperazine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
 4-phenyl-piperazine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
 15 1-cyclohexyl-3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-1-methyl-urea,
 1-(4*cis*-fluoro-cyclohexyl)-3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-1-methyl-urea,
 1-(4*cis*-fluoro-cyclohexyl)-3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-1-methyl-urea,
 20 (cis)-1-(4-methoxy-cyclohexyl)-3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-1-methyl-urea,
 (trans)-1-(4-hydroxy-cyclohexyl)-3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-1-methyl-urea,
 25 [1,4]oxazepane-4-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
 (cis)-1-(4-hydroxy-cyclohexyl)-3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-1-methyl-urea,
 2-oxa-5-aza-bicyclo[2.2.2]octane-5-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
 30 (trans)-1-(4-methoxy-cyclohexyl)-3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-1-methyl-urea,
 (1*S*,4*R*)-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
 35 3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-1-methyl-1-(tetrahydro-pyran-4-yl)-urea,
 1-cycloheptyl-3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-1-methyl-urea,
 1-cyclopentyl-3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-1-methyl-urea or
 1-cyclopentyl-3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-urea.

Preferred compounds of the present application for use against diseases, related to the A_{2a} receptor are also compounds of formula I, wherein X is -CH₂-, for example the following compounds:


- 1-oxa-8-aza-spiro[4.5]decane-8-carboxylic acid (4-methoxy-7-piperidin-1-yl-benzothiazol-2-yl)-amide,
 4-hydroxy-4-(4-methyl-benzyl)-piperidine-1-carboxylic acid (4-chloro-7-piperidin-1-yl-benzothiazol-2-yl)-amide,
 4-benzyl-piperidine-1-carboxylic acid (4-chloro-7-piperidin-1-yl-benzothiazol-2-yl)-amide,
 4-methyl-3-oxo-piperazine-1-carboxylic acid (4-methoxy-7-piperidin-1-yl-benzothiazol-2-yl)-amide or
 1-(4-chloro-7-piperidin-1-yl-benzothiazol-2-yl)-3-cyclohexyl-urea.

The present compounds of formula IA or IB and their pharmaceutically acceptable salts can be prepared by methods known in the art, for example, by processes described below, which process comprises


a) reacting a compound of formula



with phenyl chloroformate and then with a compound of formula



to a compound of formula




wherein R and X are as defined above, and R¹¹ and R²¹ form together with the N atom to which they are attached heterocyclic rings, selected from the group consisting of 2-oxa-5-aza-bicyclo[2.2.1]heptane, 3-endo-hydroxy-8-aza-bicyclo[3.2.1]octane,

- 2-aza-bicyclo[2.2.2]octane, 1-oxo-2,8-diaza-spiro[4.5]decane, 3-aza-spiro[5.5]undecane, 8-aza-spiro[4.5]decane, 1-oxa-8-aza-spiro[4.5]decane, 1,8,8-trimethyl-3-aza-bicyclo[3.2.1]octane, [1,4]oxazepane, 2-oxa-5-aza-bicyclo[2.2.2]octane, 8-oxa-3-aza-bicyclo[3.2.1]octane, 1,4-diaza-bicyclo[3.2.1]octane,
- 5 2-aza-bicyclo[2.2.1]heptane or 3-aza-bicyclo[3.2.1]octane, and which rings may be unsubstituted or substituted by lower alkyl, or is selected from piperidin-1-yl, substituted by $-(CH_2)_n$ -phenyl, $-(CH_2)_n-NR'S(O)_2$ -lower alkyl, $-C(O)NR'_2$ or $-(CH_2)_n$ -phenyl and wherein the phenyl ring is unsubstituted or substituted by lower alkyl and R' is hydrogen or lower alkyl, independently from each other in case R'_2 and n is described above,
- 10 and R^{12} is alkyl and R^{22} is cycloalkyl, substituted by one or two substituents, wherein the substituents are selected from the group, consisting of halogen, lower alkoxy or hydroxy; or

if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts.

- The compounds of formula IA and IB may be prepared in accordance with process variant
- 15 a) and with the following scheme 1. Scheme 2 shows the preparation of the intermediate compound of formula (2). 37 Examples are further described in more detail for the preparation of compounds of formula IA and IB.

Scheme 1



- 20 wherein the substituents are described above.

Preparation of a compound of formula IA or IB


To a solution of a compound of formula (2), for example 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine in dichloromethane is subsequently added pyridine and phenyl chloroformate and the resulting solution is stirred for 45 min at ambient temperature.

- 5 Then a compound of formula (3A) or (3B), for example (1S,4S)-2-oxa-5-aza-bicyclo[2.2.1]heptane is added and the mixture stirred at ambient temperature for about 15 min and at 40 °C for 2.5 h. After cooling to ambient temperature, saturated aqueous sodium carbonate is added, the organic phase is separated and dried.

The preparation of the starting compound of formula (2) has been described in EP 00113219.0 as follows:

10

Scheme 2



wherein the numbers 1 – 5 have the following meaning

- 1 morpholine or piperidine, base, Pd-catalyst,
- 2 H₂ and Pd-C, or H₂ and Raney-Ni, or TiCl₃, or Fe,
- 3 Ph(CO)NCS,
- 4 NaOMe,
- 5 Br₂.

R is lower alkoxy or halogen and R³ is piperidin-1-yl or morpholinyl.

20 Isolation and purification of the compounds

Isolation and purification of the compounds and intermediates described herein can be effected, if desired, by any suitable separation or purification procedure such as, for example, filtration, extraction, crystallization, column chromatography, thin-layer chromatography, thick-layer chromatography, preparative low or high-pressure liquid chromatography or a combination of these procedures. Specific illustrations of suitable separation and isolation procedures can be had by reference to the Preparations and

Examples herein below. However, other equivalent separation or isolation procedures could, of course, also be used.

Salts of compounds of formula IA or IB

The basic groups of compounds of formula IA or IB may be converted to a corresponding acid addition salt. The conversion is accomplished by treatment with at least a stoichiometric amount of an appropriate acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like. Typically, the free base is dissolved in an inert organic solvent such as diethyl ether, ethyl acetate, chloroform, ethanol or methanol and the like, and the acid added in a similar solvent. The temperature is maintained between 0 °C and 50 °C. The resulting salt precipitates spontaneously or may be brought out of solution with a less polar solvent.

The acid addition salts of the basic compounds of formula I may be converted to the corresponding free bases by treatment with at least a stoichiometric equivalent of a suitable base such as sodium or potassium hydroxide, potassium carbonate, sodium bicarbonate, ammonia, and the like.

The compounds of formula I and their pharmaceutically usable addition salts possess valuable pharmacological properties. Specifically, it has been found that the compounds of the present invention are adenosine receptor ligands and possess a high affinity towards the adenosine A_{2A} receptor and a good selectivity towards A₁ and A₃ receptors.

The compounds were investigated in accordance with the test given hereinafter.

Human adenosine A_{2A} receptor

The human adenosine A_{2A} receptor was recombinantly expressed in chinese hamster ovary (CHO) cells using the semliki forest virus expression system. Cells were harvested, washed twice by centrifugation, homogenised and again washed by centrifugation. The final washed membrane pellet was suspended in a Tris (50 mM) buffer containing 120 mM NaCl, 5 mM KCl, 2 mM CaCl₂ and 10 mM MgCl₂ (pH 7.4) (buffer A). The [³H]-SCH-58261 (Dionisotti et al., 1997, Br J Pharmacol 121, 353; 1nM) binding assay was carried out in 96-well plates in the presence of 2.5 µg of membrane protein, 0.5 mg of Ysi-poly-l-lysine SPA beads and 0.1 U adenosine deaminase in a final volume of 200 µl of buffer A. Non-specific binding was defined using xanthine amine congener (XAC; 2 µM). Compounds

were tested at 10 concentrations from 10 μ M - 0.3 nM. All assays were conducted in duplicate and repeated at least two times. Assay plates were incubated for 1 hour at room temperature before centrifugation and then bound ligand determined using a Packard Topcount scintillation counter. IC₅₀ values were calculated using a non-linear curve fitting program and Ki values calculated using the Cheng-Prusoff equation.

The preferred compounds show a pKi > 7.5.

Example No.	hA ₂ (pKi)	Example No.	hA ₂ (pKi)
1	8.5	19	8.4
2	7.9	20	8.5
3	8.1	21	8.6
4	8.2	22	7.8
5	8.2	23	8.1
6	7.7	24	8.0
7	8.1	25	7.7
8	8.4	27	7.9
9	7.9	28	7.9
10	8.0	29	7.9
11	8.2	30	8.3
12	8.6	32	7.6
13	8.6	33	8.3
14	8.1	34	7.8
15	8.1	35	7.9
16	7.8	36	8.1
17	7.7	37	8.1

18	7.7		
----	-----	--	--

The compounds of formula I and the pharmaceutically acceptable salts of the compounds of formula I can be used as medicaments, e.g. in the form of pharmaceutical preparations. The pharmaceutical preparations can be administered orally, e.g. in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or
5 suspensions. The administration can, however, also be effected rectally, e.g. in the form of suppositories, parenterally, e.g. in the form of injection solutions.

The compounds of formula I can be processed with pharmaceutically inert, inorganic or organic carriers for the production of pharmaceutical preparations. Lactose, corn starch or derivatives thereof, talc, stearic acids or its salts and the like can be used, for example, as
10 such carriers for tablets, coated tablets, dragées and hard gelatine capsules. Suitable carriers for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like. Depending on the nature of the active substance no carriers are, however, usually required in the case of soft gelatine capsules. Suitable carriers for the production of solutions and syrups are, for example, water, polyols, glycerol, vegetable oil
15 and the like. Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.

The pharmaceutical preparations can, moreover, contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still
20 other therapeutically valuable substances.

Medicaments containing a compound of formula I or a pharmaceutically acceptable salt thereof and a therapeutically inert carrier are also an object of the present invention, as is a process for their production, which comprises bringing one or more compounds of formula I and/or pharmaceutically acceptable acid addition salts and, if desired, one or
25 more other therapeutically valuable substances into a galenical administration form together with one or more therapeutically inert carriers.

In accordance with the invention compounds of formula I as well as their pharmaceutically acceptable salts are useful in the control or prevention of illnesses based on the adenosine receptor antagonistic activity, such as Alzheimer's disease, Parkinson's
30 disease, neuroprotection, schizophrenia, anxiety, pain, respiration deficits, depression, asthma, allergic responses, hypoxia, ischaemia, seizure and substance abuse. Furthermore, compounds of the present invention may be useful as sedatives, muscle relaxants,

antipsychotics, antiepileptics, anticonvulsants and cardioprotective agents and for the production of corresponding medicaments.

The most preferred indications in accordance with the present invention are those, which include disorders of the central nervous system, for example the treatment or
5 prevention of certain depressive disorders, neuroprotection and Parkinson's disease.

The dosage can vary within wide limits and will, of course, have to be adjusted to the individual requirements in each particular case. In the case of oral administration the dosage for adults can vary from about 0.01 mg to about 1000 mg per day of a compound of general formula I or of the corresponding amount of a pharmaceutically acceptable salt
10 thereof. The daily dosage may be administered as single dose or in divided doses and, in addition, the upper limit can also be exceeded when this is found to be indicated.

Tablet Formulation (Wet Granulation)

	<u>Item</u>	<u>Ingredients</u>	<u>mg/tablet</u>			
			5 mg	25 mg	100 mg	500 mg
15	1.	Compound of formula I	5	25	100	500
	2.	Lactose Anhydrous DTG	125	105	30	150
	3.	Sta-Rx 1500	6	6	6	30
	4.	Microcrystalline Cellulose	30	30	30	150
	5.	Magnesium Stearate	1	1	1	1
20		Total	167	167	167	831

Manufacturing Procedure

1. Mix items 1, 2, 3 and 4 and granulate with purified water.
2. Dry the granules at 50°C.
3. Pass the granules through suitable milling equipment.
- 25 4. Add item 5 and mix for three minutes; compress on a suitable press.

- 18 -

Capsule Formulation

<u>Item</u>	<u>Ingredients</u>	<u>mg/capsule</u>			
		5 mg	25 mg	100 mg	500 mg
1.	Compound of formula I	5	25	100	500
5 2.	Hydrous Lactose	159	123	148	---
3.	Corn Starch	25	35	40	70
4.	Talc	10	15	10	25
5. 5.	Magnesium Stearate	1	2	2	5
	Total	200	200	300	600

10 Manufacturing Procedure

1. Mix items 1, 2 and 3 in a suitable mixer for 30 minutes.
2. Add items 4 and 5 and mix for 3 minutes.
3. Fill into a suitable capsule.

15 The following preparation and examples illustrate the invention but are not intended to limit its scope.

Example 1

(1S,4S)-2-Oxa-5-aza-bicyclo[2.2.1]heptane-5-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

To a solution of 4-methoxy-7-morpholin-4-yl-benzothiazol-2-ylamine (265 mg, 1.0 mmol) in dichloromethane (15 ml) is subsequently added pyridine (0.24 ml, 3.0 mmol) and phenyl chloroformate (0.15 ml, 1.2 mmol) and the resulting solution stirred for 45 min at ambient temperature. Then (1S,4S)-2-oxa-5-aza-bicyclo[2.2.1]heptane (490 mg, 3.6 mmol) is added and the mixture stirred at ambient temperature for 15 min and at 40 °C for 2.5 h. After cooling to ambient temperature, saturated aqueous sodium carbonate (15 ml) is added, the organic phase is separated, dried and the solvent evaporated in vacuo. Flash chromatography (silica, eluent: dichloromethane containing methanol (gradient from 0 to 5 %)) afforded the title compound as white crystals (135 mg, 35 % yield). MS: m/e=391(M+H⁺).

Following the general method of example 1 the compounds of examples 2 to 37 were prepared.

30

Example 2

1-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-3-(tetrahydro-pyran-4-yl)-urea

Using tetrahydro-pyran-4-yl-amine, the title compound was prepared as white crystals in 62 % yield. MS: $m/e=393(M+H^+)$.

Example 3

3-*endo*-Hydroxy-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

Using 8-aza-bicyclo[3.2.1]octan-3-*endo*-ol the title compound was prepared as white crystals in 49 % yield. MS: $m/e=419(M+H^+)$.

Example 4

2-Methyl-1-oxo-2,8-diaza-spiro[4.5]decane-8-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

Using 4-spiro-[3-(*N*-methyl-2-pyrrolidinone)]piperidine, the title compound was prepared as white crystals in 43 % yield. MS: $m/e=460(M+H^+)$.

Example 5

1-Oxo-2,8-diaza-spiro[4.5]decane-8-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

Using 4-spiro-[3-(2-pyrrolidinone)]piperidine, the title compound was prepared as white crystals in 40 % yield. MS: $m/e=446(M+H^+)$.

Example 6

4-Isopropyl-piperazine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

Using 1-(2-propyl)-piperazine, the title compound was prepared as white crystals in 62 % yield. MS: $m/e=420(M+H^+)$.

Example 7

4-Phenyl-piperazine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

Using 1-phenyl-piperazine, the title compound was prepared as white crystals in 53 % yield. MS: $m/e=454(M+H^+)$.

- 20 -

Example 8

4-Benzyl-4-hydroxymethyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

Using (4-benzyl-piperidin-4-yl)-methanol, the title compound was prepared as light
5 brown solid in 6 % yield. MS: $m/e=497(M+H^+)$.

Example 9

1-Cyclohexyl-3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-1-methyl-urea

Using Cyclohexyl-methyl-amine, the title compound was prepared as white crystals in 73
% yield. MS: $m/e=405(M+H^+)$.

10 Example 10

3-Aza-spiro[5.5]undecane-3-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

Using 3-aza-spiro[5.5]undecane, the title compound was prepared as white crystals in 38
% yield. MS: $m/e=445(M+H^+)$.

15 Example 11

8-Aza-spiro[4.5]decane-8-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

Using 8-aza-spiro[4.5]decane, the title compound was prepared as white crystals in 48 %
yield. MS: $m/e=431(M+H^+)$.

20 Example 12

2-Aza-bicyclo[2.2.2]octane-2-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

Using 2-aza-bicyclo[2.2.2]octane, the title compound was prepared as white crystals in 47
% yield. MS: $m/e=403(M+H^+)$.

25 Example 13

1-Oxa-8-aza-spiro[4.5]decane-8-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

Using 1-oxa-8-aza-spiro[4.5]decane, the title compound was prepared as white crystals in
40 % yield. MS: $m/e=433(M+H^+)$.

- 21 -

Example 14

(R)-4-(1-Hydroxy-ethyl)-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

Using (R)-4-(1-hydroxy-ethyl)-piperidine, the title compound was prepared as white
5 crystals in 21 % yield. MS: m/e= 421(M+H⁺).

Example 15

(S)-4-(1-Hydroxy-ethyl)-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

Using (S)-4-(1-hydroxy-ethyl)-piperidine, the title compound was prepared as white
10 crystals in 53 % yield. MS: m/e= 421(M+H⁺).

Example 16

4-(Methanesulfonylamino-methyl)-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

Using piperidin-4-ylmethyl-carbamic acid *tert*-butyl ester, [1-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-ylcarbamoyl)-piperidin-4-ylmethyl]-carbamic acid *tert*-butyl ester was
15 prepared as white solid. Subsequent deprotection with trifluoroacetic acid and reaction with methanesulfonyl chloride/pyridine under standard conditions afforded the title compound as white crystals in 44 % overall yield. MS: m/e= 482([M-H⁺]).

Example 17

20 Piperidine-1,4-dicarboxylic acid 4-amide 1-[(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide]

Using piperidine-4-carboxylic acid amide, the title compound was prepared as white crystals in 44 % yield. MS: m/e= 420(M+H⁺).

Example 18

25 4-Methyl-3-oxo-piperazine-1-carboxylic acid (4-methoxy-7-piperidin-1-yl-benzothiazol-2-yl)-amide

Using 4-methoxy-7-piperidin-1-yl-benzothiazol-2-ylamine and 4-methyl-3-oxo-piperazine, the title compound was prepared as yellow solid in 84 % yield. MS: m/e= 404(M+H⁺).

Example 19

1-Oxa-8-aza-spiro[4.5]decane-8-carboxylic acid (4-methoxy-7-piperidin-1-yl-benzothiazol-2-yl)-amide

- Using 4-methoxy-7-piperidin-1-yl-benzothiazol-2-ylamine and 1-oxa-8-aza-spiro[4.5]decane, the title compound was prepared as beige crystals in 52 % yield. MS: m/e= 431(M+H⁺).

Example 20

4-Hydroxy-4-(4-methyl-benzyl)-piperidine-1-carboxylic acid (4-chloro-7-piperidin-1-yl-benzothiazol-2-yl)-amide

- 10 Using 4-chloro-7-piperidin-1-yl-benzothiazol-2-ylamine and 4-hydroxy-4-(4-methyl-benzyl)-piperidine, the title compound was prepared as white solid in 70 % yield. MS: m/e= 431(M+H⁺).

Example 21

1-(4-Chloro-7-piperidin-1-yl-benzothiazol-2-yl)-3-cyclohexyl-urea

- 15 Using 4-chloro-7-piperidin-1-yl-benzothiazol-2-ylamine and cyclohexylamine, the title compound was prepared as white solid in 73 % yield. MS 394(M+H⁺).

Example 22

4-Benzyl-piperidine-1-carboxylic acid (4-chloro-7-piperidin-1-yl-benzothiazol-2-yl)-amide

- 20 Using 4-chloro-7-piperidin-1-yl-benzothiazol-2-ylamine and 4-benzylpiperidine, the title compound was prepared as white solid in 80 % yield. MS 470(M+H⁺).

Example 23

1-(4*cis*-Fluoro-cyclohexyl)-3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-1-methyl-urea

- 25 Using (*cis*)-(4-fluoro-cyclohexyl)-methyl-amine the title compound was prepared as white crystals (yield 24 %), mp 201-204°C. MS: m/e=423 (M+H⁺).

Example 24

1-(4,4-Difluoro-cyclohexyl)-3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-1-methyl-urea

Using (4,4-difluoro-cyclohexyl)-methyl-amine the title compound was prepared as white crystals (yield 44 %), mp 189-192°C. MS: m/e=441(M+H⁺).

Example 25

(*cis*)-1-(4-Methoxy-cyclohexyl)-3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-1-methyl-urea

Using (*cis*)-(4-methoxy-cyclohexyl)-methyl-amine the title compound was prepared as white crystals (yield 39 %), mp 198-200 °C. MS: m/e=435 (M+H⁺).

Example 26

(1R)-1,8,8-Trimethyl-3-aza-bicyclo[3.2.1]octane-3-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

Using camphidine the title compound was prepared as white crystals (yield 75 %), mp 185-189°C. MS: m/e=445 (M+H⁺).

Example 27

(*trans*)-1-(4-Hydroxy-cyclohexyl)-3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-1-methyl-urea

Using (*trans*)-(4-hydroxy-cyclohexyl)-methyl-amine the title compound was prepared as off-white solid (yield 44%), mp 158-162°C. MS: m/e=421 (M+H⁺).

Example 28

[1,4]Oxazepane-4-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

Using [1,4]oxazepane the title compound was prepared as light-yellow solid (yield 57%), mp 171-172°C. MS: m/e=393 (M+H⁺).

Example 29

(*cis*)-1-(4-Hydroxy-cyclohexyl)-3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-1-methyl-urea

Using (*cis*)-(4-hydroxy-cyclohexyl)-methyl-amine the title compound was prepared as white solid (yield 66%), mp 169-171°C. MS: m/e=421 (M+H⁺).

Example 30

2-Oxa-5-aza-bicyclo[2.2.2]octane-5-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

Using 2-oxa-5-aza-bizyclo[2.2.2]octane the title compound was prepared as white solid
5 (yield 69%), mp 164-170°C. MS: m/e=405 (M+H⁺).

Example 31

1,4-Diaza-bicyclo[3.2.1]octane-4-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

Using 1,4-diaza-bicyclo[3.2.1]octane the title compound was prepared as light-yellow
10 crystals (yield 51 %). MS: m/e=404 (M+H⁺).

Example 32

(*trans*)-1-(4-Methoxy-cyclohexyl)-3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-1-methyl-urea

Using (*trans*)-(4-methoxy-cyclohexyl)-methyl-amine the title compound was prepared as
15 white solid (yield 48 %), mp 211-213°C. MS: m/e=435 (M+H⁺).

Example 33

(1S,4R)-2-Aza-bicyclo[2.2.1]heptane-2-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

Using (1S,4R)-2-aza-bicyclo[2.2.1]heptane the title compound was prepared as white
20 crystals (yield 67 %), mp 149 °C. MS: m/e=389 (M+H⁺).

Example 34

3-(4-Methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-1-methyl-1-(tetrahydro-pyran-4-yl)-urea

Using (4-tetrahydropyranyl)-methyl-amine the title compound was prepared as white solid
25 (yield 56 %), mp 240-242 °C. MS: m/e=407 (M+H⁺).

Example 35

1-Cycloheptyl-3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-1-methyl-urea

- 25 -

Using cycloheptyl-methyl-amine the title compound was prepared as white solid (yield 70 %), mp 198-200 °C. MS: m/e=419 (M+H⁺).

Example 36

1-Cyclopentyl-3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-1-methyl-urea

5 Using cyclopentyl-methyl-amine the title compound was prepared as white solid (yield 48 %), mp 110-125 °C. MS: m/e=391 (M+H⁺).

Example 37

1-Cyclopentyl-3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-urea

Using cyclopentylamine the title compound was prepared as white crystals (yield 57 %),
10 mp 191-194 °C. MS: m/e=377 (M+H⁺).

Preparation of intermediates for examples 1 to 22

Example 38

4-Benzyl-4-hydroxymethyl-piperidine

15 1,4-Dibenzyl-4-hydroxymethyl-piperidine (1.0 g, 3.4 mmol) in dichloromethane (20 ml) are treated with 1-chloroethyl-chloroformate (0.48 ml, 4.3 mmol, dissolved in 1.5 ml dichloromethane) and the resulting solution is stirred at 0°C for 30 min. The solvent is removed in vacuo and the resulting residue refluxed in methanol (20 ml) for 40 min. After removal of the volatile components in vacuo, the title compound is isolated by flash
20 chromatography (silica, eluent dichloromethane/methanol/triethylamine (9:1:0.1, then 4:1:0.1 followed by 3:1:0.1)) as a brown resin in 40% yield. MS 206(M+H⁺).

Example 39

1,4-Dibenzyl-4-hydroxymethyl-piperidine

Was prepared from 1,4-dibenzyl-piperidine-4-carboxylic acid ethyl ester (*J. Chem. Soc., Perkin Trans. 1* 1996, 20, 2545-2551.) by lithium aluminium hydride reduction in
25 tetrahydrofuran under standard conditions in 81% yield. MS 296(M+H⁺).

Example 40

3-Aza-spiro[5.5]undecane

Was prepared from (3,3-tetramethylglutarimide by lithium aluminium hydride reduction in tetrahydrofuran under standard conditions. Flash chromatography (silica, eluent dichloromethane/methanol/triethylamine 10:2:0.1) afforded the title compound as colorless oil (94% yield). MS 140(M+H⁺).

5

Example 41

8-Aza-spiro[4.5]decane

Was prepared from (3,3-pentamethylglutarimide by lithium aluminium hydride reduction in tetrahydrofuran under standard conditions. Flash chromatography (silica, eluent dichloromethane/methanol/triethylamine 10:2:0.1) afforded the title compound as
10 light yellow oil (>95% yield). MS 154(M+H⁺).

Example 42

(trans)-(4-hydroxy-cyclohexyl)-methyl-amine

The title compound was prepared from (trans)-(4-hydroxy-cyclohexyl)-amine by reaction with di-tert.-butyl dicarbonate in aqueous sodium hydroxide under standard conditions
15 and subsequent reduction with lithium aluminum hydride in THF under standard conditions.

If not described differently, the other N-methylated amines were prepared in the same manner.

Example 43

20 (cis)-(4-fluoro-cyclohexyl)-methyl-amine

The title compound was prepared from (cis)-(4-fluoro-cyclohexyl)-carbamic acid benzyl ester by lithium aluminum hydride reduction under standard conditions in 91 % yield.

Example 44

(cis)-(4-fluoro-cyclohexyl)-carbamic acid benzyl ester

25 (trans)-(4-hydroxy-cyclohexyl)-carbamic acid benzyl ester (900 mg, 3.6 mmol) are dissolved in dichloromethane (30 ml) and treated with diethylamino-sulfurtrifluoride (1 ml, 7.2 mmol). After 1 ha at room temperature, 5 % aqueous sodium hydrogen carbonate (15.3 g, 7.2 mmol) are added and stirring continued for another hour. The layers are separated, the aqueous phase is extracted twice with each 20 ml of dichloromethane, the
30 combined organic layers are dried with magnesium sulfate and evaporated. Flash

- 27 -

chromatography (silica, hexane containing 0 to 30 % ethyl acetate) afforded the title compound as light-yellow crystals (yield 14 %), mp 105-107°C . MS: m/e=252 (M+H⁺).

Example 45

(4,4-difluoro-cyclohexyl)-methyl-amine

- 5 The title compound was prepared from 4,4-difluoro-cyclohexanone (prepared from 8,8-Difluoro-1,4-dioxo-spiro[4.5]decane by deprotection with sulfuric acid under standard conditions) and methylamine by reductive amination under standard conditions (Pd hydroxide in methanol, 1 atm hydrogen) in ~50 % yield. Recrystallization of the hydrochloride from ethanol/diethylether afforded analytical pure material. Light-brown
10 solid, mp 137-144 °C. MS: m/e=186 (M+H⁺).

Example 46

8,8-Difluoro-1,4-dioxo-spiro[4.5]decane

- 1,4-Dioxo-spiro[4.5]decan-8-one (9.0 g, 56 mmol) and (diethylamino)sulfur trifluoride (19 g, 112 mmol) are reacted in dichloromethane (180 ml) for 2h at room temperature.
15 The mixture is poured in water (300 ml), the layers are separated and the aqueous phase back-extracted twice with dichloromethane (50 ml). The combined organic phases are dried with magnesium sulfate and evaporated. Distillation under reduced pressure over a vigreux-column afforded the title compound as colorless liquid (6.0 g, 60 %), bp 65-72°C at 13-14 mbar, MS: m/e=186 (M⁺), contaminated with ~30 % 8-Fluoro-1,4-dioxo-spiro[4.5]dec-7-ene, MS: m/e=158 (M⁺).
20

Example 47

2-oxa-5-aza-bicyclo[2.2.2]octane

- The title compound was prepared from 2-oxa-5-aza-bicyclo[2.2.2]octan-6-one (*J. Polymer Sci.* 1990, 28, 3251-60) by lithium aluminum hydride reduction under standard conditions
25 in 84% yield. MS: m/e=113 (M⁺).

Example 48

1,4-Diaza-bicyclo[3.2.1]octane

Was prepared according to the procedure published in US3,954,766 (1976). MS: m/e=112 (M⁺).

Example 49


(1S,4R)-2-Aza-bicyclo[2.2.1]heptane

The title compound was prepared from (1S,4R)-2-aza-bicyclo[2.2.1]heptan-3-one by lithium aluminum hydride reduction under standard conditions in 88 % yield. MS:

5 m/e=97 (M^+).

Claims

1. The use of compounds of the general formula



wherein

5 R is lower alkoxy or halogen;

R¹/R² are independently from each other hydrogen, lower alkyl, cycloalkyl, or tetrahydropyran-4-yl,

or R¹ and R² form together with the N atom to which they are attached heterocyclic rings, selected from the group consisting of

10 2-oxa-5-aza-bicyclo[2.2.1]heptane,
3-endo-hydroxy-8-aza-bicyclo[3.2.1]octane,
2-aza-bicyclo[2.2.2]octane,
1-oxo-2,8-diaza-spiro[4.5]decane,
3-aza-spiro[5.5]undecane,
15 8-aza-spiro[4.5]decane,
1-oxa-8-aza-spiro[4.5]decane,
1,8,8-trimethyl-3-aza-bicyclo[3.2.1]octane,
[1,4]oxazepane,

20 2-oxa-5-aza-bicyclo[2.2.2]octane,
8-oxa-3-aza-bicyclo[3.2.1]octane,
1,4-diaza-bicyclo[3.2.1]octane,
2-aza-bicyclo[2.2.1]heptane,
3-aza-bicyclo[3.2.1]octane,

25 which rings may be unsubstituted or substituted by lower alkyl, or is selected from piperazinyl, unsubstituted or mono or di-substituted by lower alkyl, phenyl or oxo, or is selected from

piperidin-1-yl, substituted by -(CH₂)_n-NR'S(O)₂-lower alkyl, -C(O)NR'₂ or -(CH₂)_n-phenyl, wherein the phenyl ring is unsubstituted or substituted by lower

- 30 -

alkyl;

R' is hydrogen or lower alkyl, independently from each other in case R'₂;X is -O- or -CH₂ and

n is 0, 1, 2, 3 or 4

- 5 and pharmaceutically acceptable acid addition salts thereof for the manufacture of medicaments for the treatment of diseases, related to the adenosine A₂ receptor system.

2. The use of compounds of formula I according to claim 1, wherein such diseases include Alzheimer's disease, Parkinson's disease, Huntington's disease, neuroprotection, schizophrenia, anxiety, pain, respiration deficits, depression, drug addiction, such as
 10 amphetamine, cocaine, opioids, ethanol, nicotine, cannabinoids, or asthma, allergic responses, hypoxia, ischaemia, seizure substance abuse, and they may be useful as sedatives, muscle relaxants, antipsychotics, antiepileptics, anticonvulsants and cardioprotective agents for disorders such as coronary artery disease and heart failure.

3. The use of compounds of formula I according to claims 1 or 2, wherein X is -O-.

- 15 4. The use of compounds of formula I according to claim 3, wherein the compound is

(1*S*,4*S*)-2-oxa-5-aza-bicyclo[2.2.1]heptane-5-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,

3-*endo*-hydroxy-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,

20 2-methyl-1-oxo-2,8-diaza-spiro[4.5]decane-8-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,

1-oxo-2,8-diaza-spiro[4.5]decane-8-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,

25 4-benzyl-4-hydroxymethyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,

3-aza-spiro[5.5]undecane-3-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,

8-aza-spiro[4.5]decane-8-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,

2-aza-bicyclo[2.2.2]octane-2-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,


1-oxa-8-aza-spiro[4.5]decane-8-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,

- (*R*)-4-(1-hydroxy-ethyl)-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
(*S*)-4-(1-hydroxy-ethyl)-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
5 4-(methanesulfonylamino-methyl)-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
piperidine-1,4-dicarboxylic acid 4-amide 1-[(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide],
1-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-3-(tetrahydro-pyran-4-yl)-urea,
10 4-isopropyl-piperazine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
4-phenyl-piperazine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
1-cyclohexyl-3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-1-methyl-urea,
15 1-(4*cis*-fluoro-cyclohexyl)-3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-1-methyl-urea,
1-(4*cis*-fluoro-cyclohexyl)-3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-1-methyl-urea,
(*cis*)-1-(4-methoxy-cyclohexyl)-3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-1-methyl-urea,
20 methyl-urea,
(*trans*)-1-(4-hydroxy-cyclohexyl)-3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-1-methyl-urea,
[1,4]oxazepane-4-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
25 (*cis*)-1-(4-hydroxy-cyclohexyl)-3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-1-methyl-urea,
2-oxa-5-aza-bicyclo[2.2.2]octane-5-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
(*trans*)-1-(4-methoxy-cyclohexyl)-3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-1-methyl-urea,
30 methyl-urea,
(1*S*,4*R*)-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide,
3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-1-methyl-1-(tetrahydro-pyran-4-yl)-urea,
35 1-cycloheptyl-3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-1-methyl-urea,
1-cyclopentyl-3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-1-methyl-urea or
1-cyclopentyl-3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-urea.

5. The use of compounds of formula I according to claims 1 or 2, wherein X is $-\text{CH}_2-$.

6. The use of compounds of formula I according to claim 5, which compounds are
 1-oxa-8-aza-spiro[4.5]decane-8-carboxylic acid (4-methoxy-7-piperidin-1-yl-benzothiazol-
 2-yl)-amide,
 4-hydroxy-4-(4-methyl-benzyl)-piperidine-1-carboxylic acid (4-chloro-7-piperidin-1-yl-
 benzothiazol-2-yl)-amide,
 4-benzyl-piperidine-1-carboxylic acid (4-chloro-7-piperidin-1-yl-benzothiazol-2-yl)-
 amide,
 4-methyl-3-oxo-piperazine-1-carboxylic acid (4-methoxy-7-piperidin-1-yl-benzothiazol-
 2-yl)-amide or
 1-(4-chloro-7-piperidin-1-yl-benzothiazol-2-yl)-3-cyclohexyl-urea.

7. Compounds of formula



wherein

R is lower alkoxy or halogen;

R^1 and R^2 form together with the N atom to which they are attached heterocyclic
 rings, selected from the group consisting of

20 2-oxa-5-aza-bicyclo[2.2.1]heptane,
 3-endo-hydroxy-8-aza-bicyclo[3.2.1]octane,
 2-aza-bicyclo[2.2.2]octane,
 1-oxo-2,8-diaza-spiro[4.5]decane,
 3-aza-spiro[5.5]undecane,
 25 8-aza-spiro[4.5]decane,
 1-oxa-8-aza-spiro[4.5]decane,
 1,8,8-trimethyl-3-aza-bicyclo[3.2.1]octane,
 [1,4]oxazepane,

2-oxa-5-aza-bicyclo[2.2.2]octane,
 8-oxa-3-aza-bicyclo[3.2.1]octane,
 1,4-diaza-bicyclo[3.2.1]octane,
 2-aza-bicyclo[2.2.1]heptane,
 5 3-aza-bicyclo[3.2.1]octane,
 which rings may be unsubstituted or substituted by lower alkyl,
 or is selected from
 piperidin-1-yl, substituted by $-(CH_2)_n-NR'S(O)_2$ -lower alkyl, $-C(O)NR'_2$ or
 $-(CH_2)_n$ -phenyl, wherein the phenyl ring is unsubstituted or substituted by lower
 10 alkyl;
 R' is hydrogen or lower alkyl, independently from each other in case R'_2 ;
 X is $-O-$ or CH_2- ; and
 n is 0, 1, 2, 3 or 4
 and pharmaceutically acceptable acid addition salts thereof.

15 8. Compounds of formula IA according to claim 7, wherein X is $-O-$.


9. Compounds of formula IA according to claim 8, which compounds are
 (1*S*,4*S*)-2-oxa-5-aza-bicyclo[2.2.1]heptane-5-carboxylic acid (4-methoxy-7-morpholin-4-
 yl-benzothiazol-2-yl)-amide,
 3-*endo*-hydroxy-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid (4-methoxy-7-morpholin-4-
 20 yl-benzothiazol-2-yl)-amide,
 2-methyl-1-oxo-2,8-diaza-spiro[4.5]decane-8-carboxylic acid (4-methoxy-7-morpholin-4-
 yl-benzothiazol-2-yl)-amide,
 1-oxo-2,8-diaza-spiro[4.5]decane-8-carboxylic acid (4-methoxy-7-morpholin-4-yl-
 benzothiazol-2-yl)-amide,
 25 4-benzyl-4-hydroxymethyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-
 benzothiazol-2-yl)-amide,
 3-aza-spiro[5.5]undecane-3-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-
 2-yl)-amide,
 8-aza-spiro[4.5]decane-8-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-
 30 yl)-amide,
 2-aza-bicyclo[2.2.2]octane-2-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-
 2-yl)-amide,
 1-oxa-8-aza-spiro[4.5]decane-8-carboxylic acid (4-methoxy-7-morpholin-4-yl-
 benzothiazol-2-yl)-amide,
 35 (*R*)-4-(1-hydroxy-ethyl)-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-

- benzothiazol-2-yl)-amide,
 (S)-4-(1-hydroxy-ethyl)-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-
 benzothiazol-2-yl)-amide,
 4-(methanesulfonylamino-methyl)-piperidine-1-carboxylic acid (4-methoxy-7-
 5 morpholin-4-yl-benzothiazol-2-yl)-amide,
 piperidine-1,4-dicarboxylic acid 4-amide 1-[(4-methoxy-7-morpholin-4-yl-benzothiazol-
 2-yl)-amide],
 (1R)-1,8,8-trimethyl-3-aza-bicyclo[3.2.1]octane-3-carboxylic acid (4-methoxy-7-
 morpholin-4-yl-benzothiazol-2-yl)-amide,
 10 2-oxa-5-aza-bicyclo[2.2.2]octane-5-carboxylic acid (4-methoxy-7-morpholin-4-yl-
 benzothiazol-2-yl)-amide,
 1,4-diaza-bicyclo[3.2.1]octane-4-carboxylic acid (4-methoxy-7-morpholin-4-yl-
 benzothiazol-2-yl)-amide or
 (1S,4R)-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid (4-methoxy-7-morpholin-4-yl-
 15 benzothiazol-2-yl)-amide.

10. Compounds of formula IA according to claim 7, wherein X is $-\text{CH}_2-$.

11. Compounds of formula IA according to claim 10, wherein the compound is
 1-oxa-8-aza-spiro[4.5]decane-8-carboxylic acid (4-methoxy-7-piperidin-1-yl-benzothiazol-
 2-yl)-amide,
 20 4-hydroxy-4-(4-methyl-benzyl)-piperidine-1-carboxylic acid (4-chloro-7-piperidin-1-yl-
 benzothiazol-2-yl)-amide or
 4-benzyl-piperidine-1-carboxylic acid (4-chloro-7-piperidin-1-yl-benzothiazol-2-yl)-
 amide.

12. Compounds of formula



wherein

R is lower alkoxy or halogen;

R¹² is lower alkyl and

R²² is cycloalkyl, substituted by one or two substituents, wherein the substituents are selected from the group, consisting of halogen, lower alkoxy or hydroxy;

X is -O- or CH₂-;

and pharmaceutically acceptable acid addition salts thereof.

5 13. Compounds of formula IB according to claim 12, wherein X is -O-.

14. Compounds of formula IB according to claim 13, wherein the compound is

1-(4*cis*-fluoro-cyclohexyl)-3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-1-methyl-urea,

1-(4,4-difluoro-cyclohexyl)-3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-1-methyl-urea,

10 (i*cis*)-1-(4-methoxy-cyclohexyl)-3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-1-methyl-urea,


(*trans*)-1-(4-hydroxy-cyclohexyl)-3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-1-methyl-urea,

15 (i*cis*)-1-(4-hydroxy-cyclohexyl)-3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-1-methyl-urea or


(*trans*)-1-(4-methoxy-cyclohexyl)-3-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-1-methyl-urea.

15 15. A process for preparing a compound of formula IA or IB as defined in claims 7 to 14, which processes comprise

a) reacting a compound of formula




with phenyl chloroformate and then with a compound of formula



25 to a compound of formula

- 36 -



- wherein R and X are as defined in claim 1, and R¹¹ and R²¹ form together with the N atom to which they are attached heterocyclic rings, selected from the group consisting of 2-oxa-5-aza-bicyclo[2.2.1]heptane, 3-endo-hydroxy-8-aza-bicyclo[3.2.1]octane, 2-aza-bicyclo[2.2.2]octane, 1-oxo-2,8-diaza-spiro[4.5]decane, 3-aza-spiro[5.5]undecane, 8-aza-spiro[4.5]decane, 1-oxa-8-aza-spiro[4.5]decane, 1,8,8-trimethyl-3-aza-bicyclo[3.2.1]octane, [1,4]oxazepane, 2-oxa-5-aza-bicyclo[2.2.2]octane, 8-oxa-3-aza-bicyclo[3.2.1]octane, 1,4-diaza-bicyclo[3.2.1]octane, 2-aza-bicyclo[2.2.1]heptane or 3-aza-bicyclo[3.2.1]octane, and which rings may be unsubstituted or substituted by lower alkyl, or is selected from piperidin-1-yl, substituted by -(CH₂)_n-phenyl, -(CH₂)_n-NR'S(O)₂-lower alkyl, -C(O)NR'₂ or -(CH₂)_n-phenyl and wherein the phenyl ring is unsubstituted or substituted by lower alkyl and R' is hydrogen or lower alkyl, independently from each other in case R'₂ and n is described above, and R¹² is alkyl and R²² is cycloalkyl, substituted by one or two substituents, wherein the substituents are selected from the group, consisting of halogen, lower alkoxy or hydroxy; or

if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts.

16. A compound according to any one of claims 7 to 14, whenever prepared by a process as claimed in claim 15 or by an equivalent method.

17. A medicament containing one or more compounds as claimed in any one of claims 7 to 14 and pharmaceutically acceptable excipients.

18. A medicament according to claim 17 for the treatment of diseases related to the adenosine receptor.

19. The use of a compound in any one of claims 7 to 14 for the treatment of diseases.

20. The use of a compound in any one of claims 7 to 14 for the manufacture of corresponding medicaments for the treatment of diseases related to the adenosine A_{2A} receptor.

- 37 -

21. The invention as hereinbefore described.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/13761

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/5377 A61K31/428 A61P25/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 01 57008 A (BASF AG ;ERICSSON ANNA (US); SCOTT BARBARA (US); ARNOLD LEE D (US)) 9 August 2001 (2001-08-09) cited in the application abstract examples 1-416 claims 23,29-32	1-20
P,Y	WO 01 97786 A (HOFFMANN LA ROCHE) 27 December 2001 (2001-12-27) abstract page 4, line 10 -page 7, line 3 page 61, line 20 -page 70, line 25 examples 358,361,380	1-20

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

25 February 2003

Date of mailing of the international search report

10/03/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Giacobbe, S

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 02/13761

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 21
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 21

Claim 21 so lacks clarity in the sense of Art 6 PCT that no meaningful search could be carried out.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 02/13761

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0157008	A	09-08-2001	AU 3669801 A EP 1254123 A1 NO 20023713 A WO 0157008 A1	14-08-2001 06-11-2002 04-10-2002 09-08-2001
WO 0197786	A	27-12-2001	AU 8181701 A WO 0197786 A2 US 2002045615 A1	02-01-2002 27-12-2001 18-04-2002